Abivax (NASDAQ:ABVX - Get Free Report)'s stock had its "overweight" rating reissued by Barclays in a note issued to investors on Tuesday, Benzinga reports. They currently have a $148.00 price target on the stock. Barclays's price target indicates a potential upside of 52.81% from the stock's previous close.
A number of other research firms also recently weighed in on ABVX. Citizens Jmp reissued a "market outperform" rating and set a $187.00 target price on shares of Abivax in a report on Wednesday, July 1st. BTIG Research boosted their price target on shares of Abivax from $150.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Citigroup restated an "outperform" rating on shares of Abivax in a research note on Tuesday, June 2nd. Piper Sandler raised their price target on shares of Abivax from $165.00 to $175.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Finally, Guggenheim reissued a "buy" rating on shares of Abivax in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $156.69.
Get Our Latest Stock Report on ABVX
Abivax Stock Up 6.4%
Shares of ABVX stock traded up $5.79 during trading on Tuesday, reaching $96.85. The company's stock had a trading volume of 1,679,970 shares, compared to its average volume of 1,283,654. The business has a fifty day moving average price of $117.40 and a 200-day moving average price of $117.18. The company has a market cap of $8.46 billion, a price-to-earnings ratio of -15.98 and a beta of 0.96. Abivax has a one year low of $69.81 and a one year high of $148.83.
Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings data on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.79). The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.80 million. Research analysts anticipate that Abivax will post -4.18 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new position in shares of Abivax in the second quarter worth approximately $284,000. Readystate Asset Management LP raised its stake in shares of Abivax by 19.6% during the second quarter. Readystate Asset Management LP now owns 241,530 shares of the company's stock worth $32,186,000 after acquiring an additional 39,508 shares in the last quarter. Troluce Capital Advisors LLC purchased a new position in shares of Abivax during the second quarter worth approximately $133,000. Seven Fleet Capital Management LP raised its stake in shares of Abivax by 158.6% during the second quarter. Seven Fleet Capital Management LP now owns 111,334 shares of the company's stock worth $14,836,000 after acquiring an additional 68,282 shares in the last quarter. Finally, FNY Investment Advisers LLC raised its stake in shares of Abivax by 7.3% during the second quarter. FNY Investment Advisers LLC now owns 7,605 shares of the company's stock worth $1,013,000 after acquiring an additional 519 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.
About Abivax
(
Get Free Report)
Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.
Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn's disease.
Recommended Stories
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
